Back to top
more

Kamada (KMDA)

(Delayed Data from NSDQ)

$5.09 USD

5.09
5,342

-0.03 (-0.61%)

Updated Apr 23, 2024 02:44 PM ET

After-Market: $5.11 +0.02 (0.39%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Kamada Ltd. [KMDA]

Reports for Purchase

Showing records 1 - 20 ( 37 total )

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 1

03/07/2024

Company Report

Pages: 7

Kedrab Distribution Agreement and IgG Portfolio Leading Near-Term Growth; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 2

11/14/2023

Company Report

Pages: 7

Approved IgG Portfolio and Kedrab Driving Near-Term Growth in 2023; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 3

08/17/2023

Company Report

Pages: 7

AAT and IgG Programs Yield Multiple Routes For Growth; Reit Buy and $11 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 4

05/25/2023

Company Report

Pages: 7

Drivers For 2023 Platform Growth, AATD Pivotal Advancement; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 5

03/16/2023

Company Report

Pages: 7

Hyperimmune IgG Portfolio-Driver For 2023 Growth; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 6

11/23/2022

Company Report

Pages: 7

Supply Agreement and IgG Portfolio Direct Near-Term Progress; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 7

08/18/2022

Company Report

Pages: 7

Hyperimmune IgG Portfolio and Supply Agreement to Drive 2022 Growth

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 8

06/08/2022

Daily Note

Pages: 4

Growth Catalysts Front and Center - Looking to 2022 Plasma Expansion

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 9

05/18/2022

Company Report

Pages: 7

Prospects for 2022 Growth-Acquired Immunoglobulins Portfolio and Commercial Expansion

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 10

03/16/2022

Company Report

Pages: 7

Specialty Plasma Diversification Positioned to Drive 2022 Platform Growth

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 11

11/23/2021

Company Report

Pages: 7

Plasma-Derived Vertical Integration Complemented By Hyperimmune Acquisition

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 12

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for KMDA

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 13

08/12/2021

Company Report

Pages: 7

Strides Towards Plasma-Derived Integration; Strategic Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 14

05/13/2021

Company Report

Pages: 7

Strategic Opportunities Across Platform Amid Backdrop of Glassia Transition

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 15

02/11/2021

Company Report

Pages: 7

Strides Taken to Broaden Plasma-Derived Platform Growth; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 16

11/12/2020

Company Report

Pages: 7

Plasma-Derived Immunoglobulin Potential in COVID-19; and Strategic Paths With Glassia Transition

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 17

08/13/2020

Company Report

Pages: 7

Progress for Plasma-Derived Hyperimmune IgG COVID-19 Therapy, Complemented by AAT Development in 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 18

05/19/2020

Company Report

Pages: 7

Plasma-Derived IgG Therapy for COVID-19, Inhaled AAT Front and Center for 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 19

02/13/2020

Company Report

Pages: 7

Planned Transition of Glassia Manufacturing Complemented by Business Development and Inhaled AAT Program Advancement

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 20

01/09/2020

Daily Note

Pages: 5

2020 Revenue Guidance Remains Strong With key Updates Expected From Phase 3 Inhaled AAT Study

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party